Beacon NewsFlashes – October 22, 2012 The MDS Beacon Phase 2 Study To Investigate Treatment For Skin Thickening Due To Chronic Graft-Versus-Host Disease – A Phase 2 study comparing Rituxan (rituximab) and Gleevec (imatinib) for the treatment of skin thickening due to chronic graft-versus-host disease is ... |
